In a 55-year-old woman taking aspirin who presents with red urine and dysuria and has a normal total cholesterol, LDL‑C at goal, low HDL‑C, and borderline elevated triglycerides, how should her lipid‑lowering therapy be adjusted?

Lipid Management Modification

This patient should have her aspirin discontinued immediately due to likely aspirin-induced hematuria, and a statin should be initiated to address her low HDL-C (38 mg/dL) and borderline elevated triglycerides (185 mg/dL), with consideration for adding a fibrate or niacin if HDL and triglycerides remain suboptimal after statin therapy.

Immediate Action: Address the Red Urine

The red urine and burning micturition after 1 week of aspirin (Ecosprin AV 150) strongly suggests aspirin-induced hematuria, a known complication of NSAID use 1. The FDA label explicitly warns that aspirin increases risk of bleeding, particularly in those over 60 years 1.

• Stop aspirin immediately and evaluate for urinary tract pathology
• Rule out urinary tract infection, stones, or other causes of hematuria
• Once bleeding resolves, aspirin can be restarted at lower dose (75-81 mg) if cardiovascular risk warrants it, or consider clopidogrel as alternative

Lipid Profile Analysis

Her current lipid values reveal:

• Total cholesterol: 162 mg/dL (acceptable)
• LDL-C: 87 mg/dL (at goal for most patients)
• HDL-C: 38 mg/dL (LOW - below target of ≥40 mg/dL for women, ideally ≥50 mg/dL) 2, 3
• Triglycerides: 185 mg/dL (borderline high - above 150 mg/dL threshold) 4, 5, 6
• VLDL: 37 mg/dL (calculated, elevated)

The primary problem is low HDL-C and elevated triglycerides, NOT elevated LDL-C.

Treatment Algorithm

Step 1: Initiate Statin Therapy

Despite LDL-C being at goal, statin therapy is indicated for this 55-year-old woman because:

• Statins provide cardiovascular benefit beyond LDL lowering 6, 7, 8
• She has atherogenic dyslipidemia (low HDL + elevated triglycerides)
• Statins modestly raise HDL-C and lower triglycerides 9

Start moderate-intensity statin (e.g., atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily) 6, 7

Step 2: Aggressive Lifestyle Modification

Mandatory interventions 4, 5, 2:

• Weight management: Target BMI 18.5-24.9 kg/m²
• Physical activity: Minimum 30-60 minutes daily, most days of the week
• Dietary changes:
  • Saturated fat <7% of total calories
  • Cholesterol <200 mg/day
  • Trans fats <1% of energy
  • Increase omega-3 fatty acids (fish 2x/week or 1g EPA/DHA capsules daily)
  • Increase fiber intake (10-25 g/day)
• Alcohol moderation: Maximum 1 drink/day for women
• Smoking cessation if applicable

Step 3: Reassess at 8-12 Weeks

After statin initiation and lifestyle changes, recheck fasting lipid panel 10:

If triglycerides remain 150-199 mg/dL and/or HDL-C remains <40 mg/dL:

• Intensify lifestyle modifications
• Continue statin therapy

If triglycerides remain 200-499 mg/dL after LDL-C goal achieved:

• Add fibrate (fenofibrate preferred over gemfibrozil with statins) OR niacin 4, 5, 6, 7
• Target non-HDL-C <130 mg/dL (calculated as total cholesterol minus HDL-C = 162-38 = 124 mg/dL, currently at goal)

If triglycerides ≥500 mg/dL:

• Prioritize fibrate or niacin BEFORE intensifying LDL therapy to prevent pancreatitis 6, 7

Step 4: Consider Combination Therapy

For persistent low HDL-C (<40 mg/dL) after statin optimization 6, 7:

• Niacin (most effective for raising HDL, 750-2000 mg/day) - monitor glucose closely 9
• Fenofibrate (safer with statins than gemfibrozil) - avoid gemfibrozil due to myopathy risk 6, 8
• Omega-3 fatty acids at higher doses (2-4 g/day) for triglyceride reduction 6, 7

Critical Safety Considerations

Statin-Fibrate Combination Warnings 6:

• Increased myopathy risk - use lowest effective statin dose
• Never combine statins with gemfibrozil - use fenofibrate only
• Monitor CK at baseline and if symptoms develop
• Monitor liver enzymes (ALT) at 8-12 weeks after initiation

Niacin Considerations 9:

• Can increase blood glucose (monitor in prediabetes/diabetes)
• Start low dose and titrate
• Prescription niacin only (not dietary supplements)

Monitoring Schedule 10:

• Lipid panel: 8±4 weeks after any medication change
• Once at goal: annually
• ALT: baseline, 8-12 weeks after starting therapy, then as clinically indicated
• CK: only if symptoms develop (not routine)

Why This Approach?

The guidelines consistently prioritize LDL-C lowering first 4, 5, 6, 7, 11, but this patient's LDL-C is already at goal. Her residual cardiovascular risk stems from atherogenic dyslipidemia (low HDL + elevated triglycerides), which requires:

1. Statin as foundation - provides pleiotropic cardiovascular benefits beyond LDL lowering
2. Lifestyle as cornerstone - most effective for raising HDL and lowering triglycerides
3. Add-on therapy if needed - fibrate or niacin for persistent abnormalities after optimizing statin and lifestyle

The 2013 ACC/AHA guidelines 6, 7 specifically state that for triglycerides 200-499 mg/dL, fibrate or niacin can be added after LDL-C goal is reached, which applies to this patient.

Common Pitfall: Do not delay statin initiation just because LDL-C is at goal - statins provide benefit through multiple mechanisms and modestly improve HDL/triglyceride profile 8.